Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Its a truly remarkable finding for an 8 year old drug designed for diabetes: Novo Nordisk is currently running two large Phase 3 trials to investigate the effect of GLP-1 drugs on Alzheimer's disease, based on early data suggesting reduced neuroinflammation, improved cognition and function, and enhanced memory, as well as trials in which GLP-1 drugs appeared to substantially reduce dementia rates in diabetes patients
It has been widely studied for its ability to: Regulate T-cell activity Reduce inflammatory cytokines such as IL-6 and TNF- Improve immune tolerance Support antiviral immunity Because many children with ASD show immune dysregulation or chronic inflammation , researchers are investigating whether immune-modulating peptides may play a supportive role
Johns Univ/NYC Health Dept, United States - Parisa Aslani, FIP Vice President, FIPWiSE Executive Sponsor, University of Sydney, Australia Watch video Digital event video 5 March 2024, 15:00 - 16:00 CET Empowering Pharmacy Technicians: Navigating Resilience in Healthcare More In this digital event, we will explore the critical role resilience plays in supporting a healthy workforce and explore strategies that pharmacy technicians can employ to strengthen it
US$ 22.03
US$ 29.42
US$ 21.56
US$ 20.79
US$ 21.35
US$ 28.12
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
